Group 1 - The company, Helit Technology (603917.SH), announced an expected net profit attributable to shareholders of the parent company for the year 2025 to be between 26 million and 36 million yuan, indicating a turnaround from a loss to profit compared to the same period last year [1]

智通财经APP讯，合力科技(603917.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润为2600万元到3600万元，与上年同期相比，将实现扭亏为盈。 ...

格隆汇1月28日丨合力科技(603917.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司 所有者的净利润为2600万元到3600万元，与上年同期相比，将实现扭亏为盈。预计2025年年度实现归属 于母公司所有者的扣除非经常性损益后的净利润为700万元到1700万元。 报告期内，公司实现业绩扭亏为盈的主要原因是公司积极开拓模具业务，公司出口模具业务产销量较上 年同期有较大幅度增长。 ...

Financial Performance Expectations - The company expects a net profit attributable to shareholders of approximately 26 million to 36 million yuan for the year 2025, marking a turnaround from a loss in the previous year[3]. - The projected net profit after deducting non-recurring gains and losses is estimated to be between 7 million and 17 million yuan for 2025[5]. - In the previous year, the company reported a net loss attributable to shareholders of 11.24 million yuan and a total profit of -15.81 million yuan[7]. - The company reported a loss of 27.68 million yuan when excluding non-recurring gains and losses in the previous year[7]. Reasons for Profit Turnaround - The main reason for the expected profit turnaround is the significant growth in the company's mold business, particularly in export sales volume compared to the previous year[9]. Earnings Forecast Details - The earnings forecast is based on preliminary calculations by the finance department and has not been audited by registered accountants[6]. - The company has communicated with its annual audit firm regarding the earnings forecast and has not identified any major uncertainties affecting its accuracy[10]. - The earnings forecast period is from January 1, 2025, to December 31, 2025[4]. Investor Advisory - Investors are advised that the forecast data is preliminary and the final financial figures will be disclosed in the official 2025 annual report[11]. - The company emphasizes the importance of investor awareness regarding investment risks associated with the preliminary earnings forecast[11].

Core Viewpoint - Helit Technology is expected to turn a profit in 2025, with projected net profit attributable to shareholders ranging from 26 million to 36 million yuan, indicating a year-on-year turnaround [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, between 7 million and 17 million yuan for 2025 [1] - The significant year-on-year change in net profit is attributed to the company's active expansion in the mold business, with substantial growth in both production and sales of exported molds compared to the previous year [1]

Core Viewpoint - The company, Helit Technology, is expected to achieve a net profit attributable to shareholders of 26 million to 36 million yuan in 2025, marking a turnaround from a loss of 11.2395 million yuan in the previous year [1] Financial Performance - The projected net profit for 2025 is between 26 million and 36 million yuan, compared to a loss of 11.2395 million yuan in the same period last year, indicating a significant improvement [1] - The expected non-recurring net profit is estimated to be between 7 million and 17 million yuan, up from a loss of 27.6795 million yuan in the previous year [1] Business Development - The anticipated profit increase is primarily attributed to the company's active expansion in the mold business, with a substantial growth in the export volume and sales of molds [1]

华泰联合证券有限责任公司 关于宁波合力科技股份有限公司 2025 年度持续督导培训情况的报告 上海证券交易所： 华泰联合证券有限责任公司(以下简称"华泰联合证券")作为宁波合力科 技股份有限公司（以下简称"合力科技"或"公司"）2022 年度向特定对象发行 股票并在主板上市持续督导阶段的保荐人，根据《证券发行上市保荐业务管理办 法》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等相关法律、法规和规范性文件的规定以及合力科技的实际情况，认真履行 保荐机构应尽的职责，对合力科技的董事、审计委员会成员、高级管理人员及中 层以上管理人员等相关人员进行了有计划、多层次的后续培训，所培训的内容严 格按照中国证券监督管理委员会及上海证券交易所有关持续督导的最新要求进 行。 2026 年 1 月 15 日，华泰联合证券相关人员完成了对合力科技主要董事、审 计委员会成员、高级管理人员及中层以上管理人员等相关人员的持续培训工作， 特向贵所报送培训工作报告。 1 进行本次培训的人员为刘栋（保荐代表人），参加本次培训的人员为合 ...

现场检查报告 华泰联合证券有限责任公司 关于宁波合力科技股份有限公司 2025 年度现场检查报告 根据中国证监会《证券发行上市保荐业务管理办法》（以下简称《保荐办法》） 和《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律 法规的要求，华泰联合证券有限责任公司（以下简称"华泰联合证券"）作为宁 波合力科技股份有限公司（以下简称"合力科技"或"公司"）2022 年度向特 定对象发行股票并在主板上市持续督导阶段的保荐人，于 2026 年 1 月 14 日至 2026 年 1 月 16 日对合力科技 2025 年度有关情况进行了现场检查。 一、本次现场检查的基本情况 华泰联合证券针对合力科技实际情况制订了 2025 年度现场检查工作计划。 为顺利实施本次现场工作，提高现场工作效率，切实履行持续督导工作，要求公 司提前准备现场检查工作所需的相关文件和资料。现场检查期间，华泰联合证券 保荐代表人根据事先制订的现场检查工作计划，采取与公司董事、监事、高级管 理人员及有关人员进行沟通和询问、查看公司生产经营场所、复核和查阅公司三 会文件等形式，对包括公司治理和内部控制情况、三会运作情况、信息披露情况、 ...

Core Insights - The expiration of the compound patent for Pyraclostrobin in China has led to a surge in domestic interest, with companies increasing registration, production, and promotion efforts [1][6] - As of 2024, there are 62 registered Pyraclostrobin products in China, including 32 active ingredients and 30 formulations, primarily targeting wheat and peanut crops [1][6] - The global market for Pyraclostrobin has seen significant growth, with sales expected to rise from $973 million in 2015 to $2.014 billion by 2024, and projected to reach $2.172 billion by 2025 [5][11] Industry Overview - Pyraclostrobin, developed by Bayer in 2004, is a broad-spectrum fungicide known for its low toxicity and effectiveness against various plant diseases [2][3] - It is particularly effective against diseases affecting cereals and legumes, making it a key product in the global fungicide market, holding an 8% market share [3][5] Market Dynamics - The Chinese market for Pyraclostrobin is expanding rapidly due to the high incidence of wheat diseases, particularly Fusarium head blight, which can cause yield losses of 10% to 20% in epidemic years [7][11] - The area affected by Fusarium head blight in China is projected to reach 15 million acres in 2024, an increase of 6 million acres from 2023 [7][8] Competitive Landscape - Major companies in the Pyraclostrobin sector include Hailir, Anhui Jiuyi, Nantong Taihe, and Guangdong Guokang, among others, with many expanding production capacity [9][10] - Hailir reported a revenue of 3.391 billion yuan in the first nine months of 2025, a 5.5% increase year-on-year, indicating strong market performance [10] Future Trends - The demand for Pyraclostrobin is expected to continue rising due to increasing occurrences of wheat diseases and advancements in application methods [11] - The market is becoming increasingly competitive, with potential oversupply leading to price fluctuations, necessitating companies to optimize production and enhance brand presence [12] - The trend towards formulation mixtures is anticipated to grow, as combining Pyraclostrobin with other chemicals can delay resistance development and enhance efficacy [13]

Core Viewpoint - The company intends to utilize temporarily idle raised funds for cash management to enhance fund efficiency and increase returns for the company and its shareholders, without affecting the normal operation of fundraising projects [3][11]. Investment Overview - **Investment Purpose**: The company aims to improve fund utilization efficiency and increase returns for shareholders by managing temporarily idle raised funds without impacting project construction [3]. - **Investment Amount**: The amount allocated for cash management is RMB 280 million [4][7]. - **Source of Funds**: The funds are sourced from temporarily idle capital raised through a specific stock issuance, totaling RMB 596.94 million, with a net amount of RMB 586.09 million after deducting related costs [5]. Investment Details - **Investment Type**: The company will invest in low-risk, principal-protected financial products, specifically structured deposits [7]. - **Investment Duration**: The investment products will have a term not exceeding 12 months [8]. Approval Process - The cash management plan was approved in the 16th meeting of the 6th Board of Directors and the 16th Supervisory Board meeting on March 31, 2025, allowing for the use of up to RMB 400 million in idle funds within a 12-month period [2][8]. Impact on the Company - The use of idle funds for cash management is designed to ensure that the necessary funds for investment projects are secured, thereby improving the utilization rate of raised funds and increasing interest income without adversely affecting the investment plans [11]. - The company will account for cash management activities in accordance with relevant financial regulations and standards [11]. Opinions from Intermediaries - Huatai United Securities confirmed that the cash management plan has followed necessary approval procedures and does not involve changing the purpose of raised funds, thus complying with regulatory requirements [13].